NUCANA PLC-ADR (NCNA)
US67022C2052 - ADR
NCNA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of NCNA have multiple concerns. NCNA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year NCNA has reported negative net income.
In the past year NCNA has reported a negative cash flow from operations.
NCNA had negative earnings in each of the past 5 years.
In the past 5 years NCNA always reported negative operating cash flow.
1.2 Ratios
NCNA's Return On Assets of -140.43% is on the low side compared to the rest of the industry. NCNA is outperformed by 83.72% of its industry peers.
NCNA has a Return On Equity of -741.68%. This is amonst the worse of the industry: NCNA underperforms 82.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -140.43% | ||
| ROE | -741.68% | ||
| ROIC | N/A |
ROA(3y)-68.88%
ROA(5y)-53.12%
ROE(3y)-110.2%
ROE(5y)-79.05%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for NCNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, NCNA has more shares outstanding
NCNA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NCNA is higher compared to a year ago.
2.2 Solvency
NCNA has an Altman-Z score of -15.21. This is a bad value and indicates that NCNA is not financially healthy and even has some risk of bankruptcy.
NCNA has a worse Altman-Z score (-15.21) than 82.30% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that NCNA is not too dependend on debt financing.
The Debt to Equity ratio of NCNA (0.04) is worse than 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.21 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
NCNA has a Current Ratio of 1.08. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.08, NCNA is not doing good in the industry: 87.26% of the companies in the same industry are doing better.
NCNA has a Quick Ratio of 1.08. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
NCNA has a worse Quick ratio (1.08) than 85.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.34% over the past year.
EPS 1Y (TTM)31.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
NCNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.95% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.3%
EPS Next 2Y19.49%
EPS Next 3Y23.99%
EPS Next 5Y24.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NCNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NCNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NCNA's earnings are expected to grow with 23.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.49%
EPS Next 3Y23.99%
5. Dividend
5.1 Amount
No dividends for NCNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUCANA PLC-ADR
NASDAQ:NCNA (12/20/2024, 8:26:39 PM)
After market: 1.21 0 (0%)1.21
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.65%
Inst Owner Change-26.95%
Ins Owners0.53%
Ins Owner ChangeN/A
Market Cap2.74M
Analysts80
Price Target22.95 (1796.69%)
Short Float %1.55%
Short Ratio0.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.83%
Min EPS beat(2)-62.57%
Max EPS beat(2)-15.09%
EPS beat(4)0
Avg EPS beat(4)-34.67%
Min EPS beat(4)-62.57%
Max EPS beat(4)-15.09%
EPS beat(8)2
Avg EPS beat(8)-31.17%
EPS beat(12)5
Avg EPS beat(12)-15.61%
EPS beat(16)6
Avg EPS beat(16)-15.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-74.29%
PT rev (3m)-85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.72%
EPS NY rev (1m)0%
EPS NY rev (3m)18.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.57 | ||
| P/tB | 1.37 | ||
| EV/EBITDA | N/A |
EPS(TTM)-14.5
EYN/A
EPS(NY)-9.38
Fwd EYN/A
FCF(TTM)-9.83
FCFYN/A
OCF(TTM)-9.63
OCFYN/A
SpS0
BVpS2.11
TBVpS0.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -140.43% | ||
| ROE | -741.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-68.88%
ROA(5y)-53.12%
ROE(3y)-110.2%
ROE(5y)-79.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 64.58% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.08 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | -15.21 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)88.98%
Cap/Depr(5y)125.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y13.3%
EPS Next 2Y19.49%
EPS Next 3Y23.99%
EPS Next 5Y24.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.38%
OCF growth 3YN/A
OCF growth 5YN/A